Study S002776

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT06256523
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 72
Start: 2022-06-29
Primary completion: 2023-09-28
Lead sponsor: Gan and Lee Pharmaceuticals, USA
Conditions: Type 2 Diabetes
Interventions: DRUG:GZR18; OTHER:Placebo
Results posted: FALSE

Registered primary outcomes

Number of adverse events and serious adverse events [29 weeks]
Changes from baseline in hemoglobin A1c (HbA1c) at the end of the study [26 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0002476	Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial. Liu M, Cell reports. Medicine	2026	Randomized trial	PMID 42320483 DOI	cites ClinicalTrials.gov:NCT06256523; registry reference DERIVED:42320483